Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Assets (2022 - 2025)

Historic Other Non-Current Assets for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $721000.0.

  • Stoke Therapeutics' Other Non-Current Assets rose 4595.14% to $721000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $721000.0, marking a year-over-year increase of 4595.14%. This contributed to the annual value of $721000.0 for FY2024, which is 2671.35% up from last year.
  • Stoke Therapeutics' Other Non-Current Assets amounted to $721000.0 in Q3 2025, which was up 4595.14% from $721000.0 recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Other Non-Current Assets peaked at $721000.0 during Q4 2024, and registered a low of $494000.0 during Q2 2024.
  • Its 4-year average for Other Non-Current Assets is $599533.3, with a median of $569000.0 in 2022.
  • As far as peak fluctuations go, Stoke Therapeutics' Other Non-Current Assets tumbled by 1318.1% in 2024, and later surged by 4595.14% in 2025.
  • Quarter analysis of 4 years shows Stoke Therapeutics' Other Non-Current Assets stood at $569000.0 in 2022, then changed by 0.0% to $569000.0 in 2023, then grew by 26.71% to $721000.0 in 2024, then changed by 0.0% to $721000.0 in 2025.
  • Its Other Non-Current Assets was $721000.0 in Q3 2025, compared to $721000.0 in Q2 2025 and $721000.0 in Q1 2025.